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Abstract (199 words) 
The use of alcohol and other drugs during pregnancy is understood to be an important public health 
problem. One way in which this problem is expressed and responded to is via the identification and 
treatment of Neonatal Abstinence Syndrome (NAS). In this paper, we demonstrate how the 
processes of anticipating, identifying and responding to NAS are characterised by significant 
uncertainty among parents and health and social care practitioners. We draw on interviews with 16 
parents who had recently had a baby at risk of NAS, and multi-disciplinary focus groups with 27 
health and social care professionals, held in Scotland, UK. NAS, and drug-use in pregnancy, is a 
fraught and complex arena. Parents in the UK who use opioids risk losing custody of children, and 
must navigate a high degree of surveillance, governance and marginalisation. We suggest that 
considering NAS as a social diagnosis, further informed by Mol’s political ontology of ‘multiple’ 
bodies/diseases, may help to produce clinical and social responses to uncertainty which avoid, 
rather than promote, further marginalisation of parents who use drugs. One such response is to 
develop a culture of relationship-based care which empowers both service providers and service 
users to challenge existing practice and decision making.  
 
Word count: 7883 
Introduction 
Neonatal Abstinence Syndrome (NAS) refers to a ‘constellation’ of symptoms associated with drug 
withdrawal in babies born to mothers who use certain types of drugs during pregnancy (Jansson & 
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Velez, 2012). It was initially popularised in a 1975 paper by Finnegan and colleagues (Marcellus, 
2007), and is regularly said to be an increasing public health problem, particularly given rising 
availability of prescription opioids in the United States and Canada (Pryor et al., 2017). NAS is 
primarily associated with opioid use during pregnancy, but has been described in babies born to 
mothers who use a range of psychoactive drugs (including cannabis, amphetamines and 
benzodiazepines), though reporting is inconsistent (Hudak et al., 2012). Indeed, there is a dearth of 
understanding about the impacts of poly-drug use on NAS, despite poly-drug use being the norm 
among certain groups of women (e.g. those who are prescribed methadone) (McQueen et al., 2015).  
NAS can be understood as a contested and controversial diagnostic label. The identification of NAS 
can lead to legal repercussions for the mother – including prosecutions for ‘child abuse’, or losing 
custody of children (Boyd, 1999; Gregory, 2010). Although NAS is said to occur in relation to an 
assortment of substances, it remains closely associated with those understood as ‘problematic’ or 
illicit. Worldwide, there are variable and conflicting responses to substance use during pregnancy – 
ranging from supportive interventions aimed at enhancing parenting capacity and child welfare, 
along with maintaining family bonds (Knopf, 2016; Morris et al., 2012; Sword et al., 2009); to 
coercive, punitive responses where drug-using pregnant women are framed as inherently unsuitable 
and dangerous, ‘notification’ to social services is mandatory, and legal measures are used to remove 
children, sometimes shortly after birth (Boyd, 1999; Flavin & Paltrow, 2010; Gregory, 2010; Kenny et 
al., 2015; Knight, 2015).  
The study of NAS, and in particular what it means to various actors involved in responding to and 
constructing the diagnosis, is essential in unpicking an already complex and contested area: drug use 
during pregnancy and early parenthood (Chandler et al., 2013; Kilty & Dej, 2012; Radcliffe, 2009). 
While there may be severe repercussions if NAS is identified, there is also a great deal of 
disagreement and variability in clinical management of such babies. NAS is identified in different 
ways, using different measures and score charts (Hudak et al., 2012; Wolff & Perez-Montejano, 
2014). Similarly, treatments for NAS differ – in some contexts, pharmacological treatment and care 
in isolated neonatal units are standard practice (Hudak et al., 2012), in others, non-invasive 
approaches which emphasise mother-child bonding in non-clinical settings are emphasised (Jansson 
& Velez, 2012; Knopf, 2016).  
Despite these variations, research on local meanings and practices relating specifically to NAS are 
limited. Wider studies addressing drug-use in pregnancy or parenthood have identified diverse 
practices relating to NAS, highlighting potentially problematic features (Boyd, 1999; Klee et al., 2002; 
Knight, 2015). However, few qualitative studies focusing specifically on NAS exist (Atwood et al., 
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2016; Benoit et al., 2014; Cleveland & Bonugli, 2014). While offering some insight into the complex 
challenges faced by parents and practitioners alike, existing studies tend to be clinically driven, 
relatively descriptive and do not engage deeply with the social, cultural or material contexts in which 
care for babies at risk of NAS takes place. Sociological attention regarding these issues is particularly 
sparse, though with regard to drug use in general, sociological perspectives have been widely and 
successfully applied (e.g. Fraser et al., 2014; Fraser & valentine, 2008). 
Our study aimed to explore understandings of NAS among parents whose babies were at risk of NAS 
(all mothers used opioids during pregnancy), and among health and social care practitioners 
experienced in working with such parents, or their babies (AUTHOR 2019). The study examined local 
understandings of NAS in two neighbouring geographical areas of Scotland, UK. To make sense of 
the multiple ways in which NAS was constructed in these accounts, and the diverse resources drawn 
upon to produce NAS, we draw on scholarship addressing the sociology of diagnosis, and specifically 
Brown’s concept of social diagnosis (2011). Uncertainty was a theme throughout the findings, and 
we reflect on the importance of working with such uncertainty for practitioners, and managing this 
for parents, particularly in the context of child protection policies and practices which mark parental, 
and especially maternal, substance use as fundamentally problematic, and drug-exposed infants as 
inherently ‘at risk’.  
Social Diagnosis and NAS 
While sociology has long been concerned with the social construction and contexts in which 
diagnosis plays out (Blaxter, 1978; Brown, 1990), the ‘sociology of diagnosis’ has received special 
attention in recent years (Jutel, 2009; Jutel & Nettleton, 2011). In this paper, we draw on the work of 
Brown and colleagues, and their concept of social diagnosis (2011).  
The concept of social diagnosis explicitly expands the scope of sociological analysis of diagnoses to 
incorporate wider structural and cultural contexts, engaging with the multiple actors and resources 
who may be engaged in diagnostic work – including sociologists (Brown et al., 2011; Shriver & 
Bodenhamer, 2018). This approach facilitates an examination of pathogenic structural and cultural 
factors which might promote or inhibit particular forms of disease, or facilitate the identification or 
diagnosis of a given disease (2011 p. 939). This is a potentially productive way of considering NAS, 
and more broadly ‘problematic’ drug use: neither is evenly spread throughout populations, but are 
more likely to be concentrated in the bodies of those who are marginalised and poor (Knight, 2015; 
Powis et al., 2000). Despite the clear relevance of social, economic and political factors, discourse 
about both NAS and problem drug often focuses on psychological or biological pathologies, with 
addiction more often framed as an individual affliction (Vrecko, 2010). Where ‘the social’ is present, 
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this tends to be limited to individual life histories marked by trauma, abuse and loss. In relation to 
drug-use and parenting (including discussions of NAS), such factors are associated with attendant 
problems with ‘attachment’ and quality of caregiving, which are then related to likely problems in 
future parenting capacity and child welfare (ACMD, 2003). The social diagnosis of NAS supports a 
sociological gaze which can take into account structural and symbolic violence as contributing to the 
material and social production of this particular condition and to understanding how and why it is 
identified in particular bodies (and, perhaps, not others). Such a gaze may have the potential effect 
of diverting attention away from individual (pathological) maternal bodies, and provide a basis for an 
active sociological intervention into ongoing debates about the governance of drug-use in the 
context of parenting.  
The concept of social diagnosis (at least as expressed in Brown et al’s 2011 paper) is more limited in 
how far it engages with intimate, embodied, material practices of diagnosis. There is a danger when 
considering broad structural and cultural issues, of losing some of the significant interpersonal, inter-
corporeal and material contexts which also ‘make up’ particular diagnostic processes. This distance 
from intimate settings may also contribute to a relative lack of engagement with resistance to 
diagnostic processes (Jenkins & Short, 2017). We propose an approach which bridges this gap: 
connecting the concept of social diagnosis to Mol’s work on the production of the ‘body multiple’ via 
different forms of clinical practice (Mol, 2002). This approach resonates with Jenkins and Short’s 
recent modification of social diagnosis, to include greater attention to processes of resistance to 
diagnosis. Like Mol’s approach to the ‘body multiple’, Jenkins and Short’s argument similarly 
underlines multiplicity in how diagnosis takes place. Drawing on debates about the identification and 
(potential) ‘treatment’ of intersex people, they note that contested or uncertain diagnoses may be 
resisted by some, at the same time that others seek to confirm or institutionalise a particular 
diagnosis and attendant treatment response.  
However, Jenkins and Short’s analysis of diagnostic resistance in the case of intersex draws on a 
literature review, and thus also maintains a distance from the interpersonal, intimate processes by 
which diagnoses may be resisted, contested or confirmed. In contrast, Mol’s ethnographic approach 
engages directly with the rich and multi-layered manner in which diagnosis proceeds in different 
clinical settings, addressing diversities among material resources; healthcare systems and 
organisations, clinical specialities, with their attendant priorities and policy drivers; and diverse ‘lay’ 
actors, who also draw on available cultural and social resources through which they can make sense 
of and respond to a diagnosis. Importantly, Mol’s work allows analysts to view a ‘diagnosis’ as 
multiple. In the case of NAS, as we will demonstrate, this is particularly apposite, since the ‘NAS’ that 
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is talked of (and feared) by parents, is not necessarily the same as the ‘NAS’ that is produced by 
particular score charts, or the ‘NAS’ that is discussed by social work practitioners as a risk factor 
endangering a child’s future health. Similarly the ‘NAS’ that midwives working on a standard 
postnatal ward describe might be different from the ‘NAS’ that is responded to in a specialist 
neonatal unit (NNU). The coexistence of multiple enactments of NAS contributes to – but does not 
constitute – the uncertainty that we identify across narratives of different social actors involved in 
caring for babies who might be affected by NAS. 
Methods 
This paper is based on a qualitative study of the accounts of 16 parents and 27 practitioners 
regarding experiences of preparing for and caring for babies at risk of developing NAS. The research 
was carried out by a multi-disciplinary team of social scientists and clinicians, including an 
obstetrician, neonatologist and addictions nurse. The aims of the research were to explore 
understandings and responses to NAS among parents and practitioners. We conducted individual 
interviews with parents of babies who were at risk of NAS, alongside multi-disciplinary focus groups 
with health and social care practitioners who were involved in the care of families affected by NAS.   
Parents were recruited during pregnancy, and interviews arranged between 1 month and 6 months 
after babies were born. Recruitment was supported by healthcare practitioners, who approached 
opioid-dependent women during pregnancy (e.g. women known to services as opioid dependent, in 
most instances receiving a prescribed opioid-substitute such as methadone). Most participants were 
informed of the study by their midwives. If women expressed initial interest, they were provided 
with a participant information sheet, and advised that a researcher would call to discuss further. A 
phone call was held with interested women, where the research was discussed and explained in 
more detail. At this point, the researcher raised the possibility of also interviewing the father (social 
or biological) of the baby. Given high rates of domestic violence experienced among drug-dependent 
women (Radcliffe et al., 2016), we felt women should hold as much power as possible as to whether 
their partners were involved in or aware of the research. For women who were still interested, an 
agreement was made to make further phone contact after the due date, to check in and – if still 
desired– arrange a time and place for the interview. If women suggested their partner could be 
contacted, they were called and the research discussed to gauge whether they were interested in 
taking part in a separate interview.  
Interviews addressed parents’ history of drug use, contextual features of their lives, experiences 
during and after pregnancy, with a particular focus on NAS, and interactions with health and social 
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care providers. Interviews with couples were held separately. In most cases, interviews were held in 
participants’ homes. 
Alongside the interviews, four interdisciplinary focus groups were conducted with 27 health and 
social care practitioners who worked with parents who use drugs, or babies at risk of NAS. 
Participants were recruited through researchers’ existing and well-established links with 
practitioners. Focus groups addressed participants’ experiences of working with parents on the issue 
of NAS; recognising and supporting babies experiencing NAS. Professional staff were recruited 
because of their experience in working with opioid-dependent parents, and included social workers, 
early years workers, midwives, neonatal nurses, General Practitioners, consultant psychiatrists, 
obstetricians and neonatologists, addictions nurses, and health visitors (child health nurses). Focus 
group participants were recruited through the multidisciplinary research team’s substantial 
networks across health and social care services in the areas studied, with potential participants sent 
email invitations to gauge initial interest. The focus groups were facilitated by two researchers, so 
that notes could be taken about interactions, group dynamics and non-verbal communication 
between group members. 
The study was held in two neighbouring areas of Scotland, UK. Area 1 includes a large city, Area 2 a 
large town. Each area incorporates urban and semi-rural populations. The majority of parents 
interviewed lived in Area 1, with six in Area 2 (three couples). Similarly, the majority of professional 
participants worked in Area 1, with the exception of four participants, including a neonatal nurse, 
who worked in Area 2. Maternity care and drug services are organised slightly differently in each 
area. In particular, urban areas within Area 1 are served by a specialist, multidisciplinary team which 
cares for pregnant women who are drug or alcohol dependent, and whose substance use is judged 
to be particularly ‘risky’ (to themselves, and their future child).  
Interviews and focus groups were digitally audio-recorded, transcribed, anonymised and uploaded 
to NVIVO 10 (QSR International Pty Ltd., 2012). The data were analysed using inductive coding, 
drawing on narrative and discursive approaches (Hennink et al., 2011; Riessman, 2008). We were 
interested in how participants talked about – and constructed – NAS in their accounts. All interview 
and focus group transcripts were initially subject to broad, inductive content coding by Chandler and 
Whittaker. Following this, particular broad codes of interest were examined in more detail, subject 
to multiple re-readings, with further sub-codes developed. In this paper, we address a number of 
related codes that might be characterised as addressing ‘NAS talk’. This included discussion about 
the causes, identification and treatment of NAS. 
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The research was reviewed and approved by the local NHS Research Ethics Committee. All 
participants provided informed, written consent before data collection; data were fully anonymised 
and confidentiality maintained. Interviewees received a £20 gift voucher as a token of thanks for 
their time and commitment to the study. Focus group participants were provided with lunch.   
Findings 
Sample 
16 parents took part in interviews: 7 fathers, and 9 mothers, which included 7 heterosexual couples 
who were interviewed separately (see Table 1). Parents were aged between 23 and 47, all but two 
fathers reported current use of opioids, or opioid substitution therapy (methadone, buprenorphine, 
dihydrocodeine). The majority of the sample reported poly-drug use (including anti-depressant 
prescriptions, benzodiazepines – prescribed and non-prescribed, cannabis, tobacco and alcohol). 
Participants talked of living with a range of challenging circumstances. All but one of the participants 
were unemployed: worries about money were ubiquitous. All were living in social housing 
(government subsidised), or described unstable housing, including recent periods of homelessness. 
Twelve participants described previous involvement in the criminal justice system, with nine 
indicating they had spent time in prison. The majority of participants described limited social 
support, being estranged from family members and having severed contact with previous 
‘acquaintances’ who continued to use drugs. 
[Add Table 1 here] 
All of those who took part in the study had custody of their babies at the time of interview. 
However, six mothers, and five fathers had older children with whom they had limited or no contact. 
For mothers, this was because children were in the care of others (e.g. they had lost custody); for all 
but one of the fathers this followed a previous relationship breakdown and estrangement or 
antagonistic relationships with ex-partners. Four mothers had custody of at least some of their older 
children.  
All participants who described themselves as drug dependent were engaged in drug treatment. 
Mothers were enrolled on opioid substitution programmes, most were prescribed methadone, with 
one mother indicating she transferred from methadone to buprenorphine (Subutex) during her 
pregnancy, and another transferring from methadone to dihydrocodeine. Nine participants 
described mental health problems, primarily anxiety and depression. Two couples were managed by 
the multidisciplinary, specialist substance use in pregnancy care team operating in the urban section 
of Area 1. All other participants received standard maternity care alongside their drug treatment 
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programmes. Drug treatment in Scotland can be provided via primary care or by specialist NHS 
addictions teams.  
Health and social care practitioners who took part in the focus groups were all experienced 
professionals, who had spent at least five years in their current role. Table 2 provides an overview of 
focus group participants. Three of the four focus groups included staff from the specialist substance 
use in pregnancy team. 
[Add Table 2 here] 
Anticipating the diagnosis, negotiating uncertain causality 
The diagnosis or identification of NAS is anticipated during pregnancy, a time where discussions 
between parents and healthcare providers may begin to address the possibility of NAS, and any 
steps which could be taken to ameliorate risk of NAS. Indeed, a key concern across both interviews 
and focus groups was the question of whether or not NAS could be prevented and – relatedly – what 
‘caused’ NAS. Interviewees and focus group participants all readily acknowledged the 
‘unpredictability’ of NAS. This was a common narrative, often supported by anecdotal evidence, 
which was employed to emphasise that the symptoms of NAS did not correlate neatly with the 
amount or type of drugs used by women during pregnancy.  
“…you could have a really bad habit with heroin and your baby could come out fine.  You 
could be on a really low dose of dihydrocodeine and your baby could have really bad 
symptoms or the other way about.  It just, kind of, totally depends on the baby itself.  
Everybody’s different” Hayley 
“Even the ones that are on a lower dose and generally quite stable, who, like you said, it’s 
really unpredictable as to whose baby is going to withdraw” Health Visitor, FG#3 
However, despite wide acknowledgement of the ‘unpredictability’ of NAS symptoms in relation to 
opioid use (Cleary et al., 2010), professionals and parents nonetheless focused on reducing drug use 
(including prescribed drug use) when discussing how to minimise symptoms or incidence of NAS. 
Here, Hayley responds to a question about advice she would give to other mothers whose babies 
were at risk of NAS, despite earlier in her interview referring to guidance she had been given by her 
addictions team about the unpredictable nature of NAS: 
“I definitely think there’s something in the…if you’re on methadone, being on 
dihydrocodeine is a bit better.  […] So I would maybe say about that, try and get low on that, 
obviously try and come off it if possible but if not try and go on to dihydrocodeine because it 
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will stay in your system a lot less time.  Just try and do everything you can do to make it as 
least chance possible that the baby’s going to… [withdraw]” Hayley 
Hayley’s account drew on her own experience of transferring from prescribed methadone to 
dihydrocodeine during pregnancy, and having a baby who was framed as exhibiting only ‘mild’ 
symptoms. However, reflecting the ‘unpredictability’ of NAS, other participants who had not 
reduced methadone dosage, or who had continued to use illicit drugs during pregnancy, also 
described babies who were ‘fine’ and had ‘mild’ or no symptoms of NAS. 
Despite acknowledgement of unpredictability, focusing on maternal drug use as a cause of NAS led 
to some interviewee and focus group participants providing narratives which alluded to ‘blaming’ 
mothers when babies exhibited symptoms of NAS:  
“I have to say sometimes when I see…when I've got a baby who is not feeding, not sleeping, 
and who is all extended and you know, you think to yourself, oh, and it's so hard not to 
blame the mum, you know, you know yourself, it's trying to rationalise it” Neonatal Nurse, 
FG#1 
“Interviewer: But [can you talk about] why some of them [babies with NAS symptoms] are 
really bad and some of them are not so bad. 
Liam (father): Just luck nae doubt.  It probably depends what the mum’s been up to.  If the 
mum’s been taking more drugs.  No doubt, most people you speak to lie to you about what 
they’ve taken.  I can guarantee it, nobody will tell you the truth” 
 
Accounts which focused on maternal drug use as a cause of severe symptoms emerged frequently. 
As in the quote from Liam’s interview, this often went alongside a suggestion (posed by parents and 
professionals) that mothers would not be truthful about their drug use. This narrative coexisted 
uneasily with acknowledgement of the ‘uncertainty’ of the relationship between maternal drug dose 
and severity of NAS.  
Uncertainty and diagnosis: scoring babies for NAS 
Uncertainty regarding NAS extends to the postnatal period, where babies may be monitored for 
signs of withdrawal. Parents talked of anxieties during pregnancy as to whether their baby might 
‘have NAS’ when it was born. However, in many cases, they spoke of a lack of clarity and 
inconsistency when discussing the identification or diagnosis of NAS once babies had arrived. This 
theme emerged especially when discussing the use of ‘score charts’ to assess babies for presence 
and severity of symptoms of NAS. In both areas studied, best practice guidance encourages 
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involvement of parents in monitoring babies for signs of NAS, using either an adapted version of 
Finnegan’s Neonatal Abstinence Score Sheet (Area 1) or the Lipsitz Scoring Tool (Area 2)i. However, 
interviews indicated that in practice parental involvement in scoring was variable. In particular, 
parents who were involved with the specialist team in Area 1 indicated that they were prepared for 
the use of a NAS score chart, and encouraged to use it themselves by staff in the team. In contrast, 
several parents managed by standard maternity services indicated little awareness of the existence 
of such score charts. Further, parents managed on the postnatal wards suggested scoring was 
something done by professional staff alone, with no parental involvement. Several parents reported 
having to ask staff directly about their baby’s score, suspecting that had they not asked the chart 
would not have been mentioned. Joanne was managed by the specialist team and said she had 
expected to be involved in scoring her baby’s NAS symptoms: 
“They never even spoke about - like they never even really spoke about the score sheet.  I 
thought it was going to a bigger deal than what it was cause, [specialist midwife], sat and 
told me all about it one time, Mike [father], was at his group and [the midwife] said that the 
nurses will go through with me and they’ll do it with me in the hospital but nobody ever, 
nobody ever mentioned her score sheet in the hospital until I mentioned” Joanne 
Accounts about parents not being involved in scoring their babies for symptoms of NAS can be 
understood in a wider context of stigma towards drug using parents, and the threat of losing custody 
if deemed not to be ‘good enough’. Parents’ knowledge of the status of their baby in regards to NAS 
was framed as important, relating to normative concerns with presenting themselves (to staff, the 
interviewer, themselves) as ‘good parents’ – interested in their baby’s wellbeing. For many parents 
in our sample this was of special significance, as they had lost custody of older children and were 
highly sensitised to the risks they faced of losing custody of their youngest child if they were not 
deemed by statutory services to be ‘good enough’ parents (Chandler et al., 2013, 2019; Rhodes et 
al., 2010). 
Where babies did appear to have more significant symptoms of NAS, the score chart became a more 
contentious issue. Shelley and Ryan’s baby was described as showing some signs of NAS. As well as 
being concerned about the symptoms experienced by their baby, the couple spoke of inconsistent 
messages from staff, and feeling excluded from involvement in the monitoring and care of their 
baby.  
“They didn’t even tell me they were doing the test [score chart] half the time. I just knew 
because the first time they did it, do you know what I mean, and they would fill out the wee 
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thing [score chart] in front of you but they never ever let you see it.  I had to ask to see it” 
Shelley  
Across accounts of scoring, parents frequently positioned themselves as relatively powerless – 
knowledge of their baby’s NAS status was kept from them by professionals, despite local policies 
that they be involved in monitoring. At the same time, parents’ accounts spoke of attempts to resist 
this exclusion – asking to see score charts, and presenting themselves as knowledgeable and 
interested in their baby’s care.  
The uncertainty of NAS scoring featured throughout these accounts – with frequent tales of 
disagreements between different staff, and between parents and staff, about the nature and 
interpretation of a baby’s symptoms.  These disagreements became particularly acute when 
considering the potential (threat) of care in the Neonatal Unit (NNU).  
Uncertainty and diagnosis: treatment and admission to NNU 
Only three participants (including a couple) said their baby was admitted to NNU, and neither of 
these cases were said to be due to NAS. In other interviews, admission to the NNU was marked as a 
clear sign that NAS was severe, and that therefore the mother must have been using illicit drugs.  
“I’ve seen with other mums, one girl’s dabbling [taking illicit drugs], still kept dabbling 
compared to me and like, just sticking with methadone, and she’s no getting her baby home.  
[…] her baby’s, well, it’s in the [neo]natal unit now so it’s like, do you know what I mean, 
your baby’s really sick even though you knew the risks” Joanne 
Joanne’s baby was not treated in NNU, and in the excerpt above she suggests that use of illicit drugs 
(‘dabbling’) was a key difference between her and an acquaintance whose baby was treated in NNU 
and who was also not granted custody (‘no getting her baby home’). Again, despite 
acknowledgement of uncertainty, more ‘severe’ NAS is associated here with more ‘severe’ drug use 
– in this case using illicit opioids in addition to prescribed methadone. Treatment in NNU emerged 
across the accounts as a clear signifier of ‘severe’ NAS. 
Shelley and Ryan referred to staff members providing inconsistent scores on the NAS chart, and 
different conclusions as to what form of care would be provided. Both suggested there had been a 
dispute over whether their baby should be admitted to NNU and treated with opioids in order to 
relieve symptoms.  
“…they would come and tell you, just for instance, “I think, oh she’s only scoring a seven” 
and then we would talk to the midwife later:  “oh she’s scoring a nine”.  I says, “well the one 
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told us seven earlier”.  And then another time they were saying, “oh she’s scoring a nine”, 
and then the next thing, “she’s scoring 11”.  But the woman was saying “if it ever goes past a 
then they go straight to special baby care”” Ryan 
Ultimately, Shelley and Ryan’s baby was not admitted to NNU, but in both interviews the ‘threat’ of 
admission was presented as extremely stressful. Disagreement between parents and medical staff 
about the diagnosis and treatment of a baby is especially highly charged in the case of NAS – as 
noted across several interviews, a diagnosis of NAS was understood (and experienced) by some to 
invoke additional involvement from statutory social work and child protection. Freddie, when 
reflecting on his concerns about his partners’ pregnancy and drug use, noted that “basically, how I 
saw it if the baby’s got NAS you aren’t getting your baby”. These accounts underline the moral and 
legal significance of the ‘diagnosis’ of NAS – with admission to NNU marked as a particularly strong 
sign a baby had been negatively affected by maternal drug use, which was then connected (by 
parents and professionals) to parents (mothers’) (in)ability to care for their baby at home.  
Uncertainty and diagnosis: naming NAS 
Across focus groups with professional staff, contrasting views were raised regarding the importance 
of ‘naming’ NAS, and communicating this to parents. This concern sat uneasily with the concurrent 
narrative that identifying NAS could be challenging, since symptoms may or may not be related to 
maternal drug use and dose. Uncertainty about naming NAS was reflected in interviews with 
parents, who tended not to talk about babies as being diagnosed with NAS, but rather of ‘some 
signs’ or ‘a low score’. Eilidh, for instance, who said her baby was admitted to the neonatal unit for 
assistance with feeding (not for NAS), reported that her baby: 
“…did have slight NAS, but … not concerning, but enough to make you feel really guilty” 
Eilidh 
In Eilidh’s account, and among other parents, the presence or absence of NAS, whether and to what 
extent different symptoms exhibited by babies could be attributed to NAS or something else, often 
shifted and lacked clarity. It is important to note that these accounts are produced in a context 
where maternal drug use is highly stigmatised, mothers are framed as morally culpable, and parents 
face very real legal challenges regarding the custody of their children. Thus, parents’ accounts must 
navigate a complex terrain – acknowledging NAS, but minimising effects to some extent, claiming 
‘guilt’, whilst also trying to live comfortably with their status as (partner of) a ‘drug-using mother’ 
who faces blame/shame from multiple sources (Whittaker et al. 2019).  
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In focus groups with professionals, accounts from parents which avoided naming NAS were framed 
as ‘minimising’ the diagnosis of NAS. In Focus Group 1, a discussion between a community midwife 
and neonatal nurse suggested there was a ‘problem’ with more junior staff failing to clearly 
communicate a diagnosis of NAS to parents.  
Midwife: Yes, and there is, we do get a few woman, you're right, that don't acknowledge 
and they will try anything else to say, oh it's feeding problems, it's not to do with NAS, and 
we do try and tell them it is, because it is quite important for them to acknowledge that it is 
Neonatal Nurse: But, the reason for that probably is because a lot of the staff who are 
junior, skirt around the issue with parents. 
An interesting contrast can be drawn between the midwife’s insistence on the importance of 
parents ‘acknowledging’ a baby’s symptoms are related to NAS, and the simultaneous narrative that 
NAS was an uncertain label. The exchange also shows how clinical and social contexts shape 
uncertainty – some staff may avoid labelling baby’s with NAS, perhaps because of their own 
uncertainty, perhaps because they might see a label of NAS as an unnecessary burden for parents to 
bear, perhaps because a label of NAS is not necessary in order to provide care for a baby exhibiting 
symptoms. In contrast, the midwife, who worked in community settings with pregnant and postnatal 
women who used drugs, argued that naming NAS – and parents acknowledging NAS explicitly – was 
important. This related to a strong narrative among some professionals that parents should ‘take 
responsibility’ for their drug use and the (potential) impacts it might have on their children.  
Uncertainty around the diagnosis of NAS was reflected starkly in Joanne and Mike’s account of their 
baby’s ‘NAS status’ changing according to which healthcare professional they were dealing with.   
“No, she [Health Visitor] was…she used a score sheet as well.  But it went really down, I 
mean, after the…when the midwife left, we got a new bloody health visitor and she was 
saying, oh she’s stretching. That’s NAS. If she’s crying a lot, that’s NAS. If she’s having a burp, 
that’s NAS. We went, what? You’re joking” Mike 
Mike and Joanne each provided accounts where staff on the postnatal ward had scored their baby 
increasingly ‘low’ on the NAS chart, and their community midwife had reassured them that their 
baby was doing well with no signs of NAS. However, on transfer at 10 days postnatal to the 
community health visitor, they were told that a wide range of ‘symptoms’ (none of which had been 
recorded on the NAS chart they used) could be signs of NAS. For Joanne and Mike – as with other 
parents – uncertainty was exacerbated by apparent conflicts in the perspective of individual staff 
regarding whether their baby ‘had NAS’, the impact of different practices of identification and 
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measurement of symptoms, and the related introduction of a range of apparently disparate 
symptoms that were attributed to NAS (by the health visitor), but which were not recorded on the 
NAS chart. It is important to note that in highlighting this case of uncertainty we are not suggesting 
that a more detailed score chart could have avoided this, made a diagnosis more certain. Rather, this 
case underlines the instability of NAS, with subtle but important differences between clinical 
practitioners and contexts of care shaping how NAS is understood and – in Mol’s (2002) terms – 
enacted. Such subtle differences nonetheless have far-reaching consequences with regards to NAS, 
identification of which is associated, as we have demonstrated, with significant maternal/parental 
guilt and blame (see also Whittaker et al. 2019).    
Discussion 
Uncertainty in medicine has long been a topic of sociological inquiry (Atkinson, 1984; Fox, 2000). In 
this paper we have shown how uncertainty emerges in accounts of parents and professionals when 
talking about Neonatal Abstinence Syndrome. As has been shown with other conditions, such as 
Attention-Deficit Hyperactivity Disorder, we found that uncertainty was a feature of talk not just 
about diagnosis, but also regarding causes and treatments of NAS (Rafalovich, 2005). With NAS the 
uncertainty that is a feature of conversations about causality, diagnosis, assessment and treatment 
is particularly fraught due to moral framings and potential legal implications of drug-use in 
pregnancy (Boyd, 2004). Indeed, our analysis suggests that uncertainty about NAS means that 
accounts can simultaneously hold the diagnosis and cause of NAS as uncertain, and nevertheless still 
‘blame mothers’ for ‘causing’ NAS or the possibility of NAS.  
 NAS can be understood as a social diagnosis, following Brown et al.’s (2011) concept. It is produced 
by particular political and socioeconomic conditions, though such a reading is rarely foregrounded 
either in clinical contexts, or in our data. An  explicitly political or macro-view of drug use – and 
outcomes such as NAS – was largely absent in our interviews with parents and professionals, but 
those conditions nonetheless can be understood as shaping the experience of NAS, or its 
potentiality, for both health and social care professionals as well as for drug using parents. There 
was direct evidence of parents’ experiences of powerlessness, of feeling marginalised in decisions 
being made about their own lives and that of their children, in a context where the ultimate threat 
of losing custody of children was ever-present. These accounts also pointed to the legal and moral 
frameworks that surround maternal drug use, and which propel the apparent need to diagnose or 
‘name’ NAS, as well as feeding debates about the causes of NAS. We find that despite inherent 
uncertainty with regard to both the causes and identification or diagnosis of NAS, current ‘logics of 
care’ (Whittaker et al. 2019) are enrolled around a focus on individual mothers and their behaviours.  
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Although biomedical framings persist, despite diagnostic uncertainties, these are clearly inflected 
with notions of moral toxicity. 
Brown et al’s (2011) explication of social diagnosis does much to shift the focus of diagnosis away 
from individual bodies, and onto social and political structures which may also be ‘diagnosed’ as 
contributing to pathology. In this respect it is useful in allowing a wider reading of the ambiguities 
and uncertainties that our data and analysis demonstrate are played out in clinical settings. 
However, this framework has less to offer in terms of considering the intimate, interpersonal 
contexts in which diagnosis (by multiple social actors) may play out. This issue has been addressed 
partly in a later paper by Jenkins and Short (2017), who identified the role of resistance to diagnoses 
as part of any consideration of social diagnosis. However, in each case, practices of diagnosis are left 
relatively untouched. It is here that Mol’s (2002) ethnographic orientation towards practices and 
meaning-making in relation to the identification of disease by different medical specialities offers 
additional analytic traction to the concept of social diagnosis. This relates to a need to ‘bring bodies 
back in’ as well as considering the social inscriptions within which they are understood. 
Paralleling Mol’s (2002) arguments about the coexistence of multiple bodies, and multiple 
enactments of atherosclerosis in a Dutch hospital; our analysis shows that NAS too can be seen as 
multiple: produced, or enacted, in different ways, through different practices in different places. In 
the accounts we generated and analysed, NAS was described as being identifiable through different 
types of score chart, through accumulated professional or lay knowledge and experience. In some 
cases, NAS was anticipated by parents and some professionals, it was searched for, expected: it 
retained power as a potentiality even if diagnostic criteria were contested or absent. However, this 
expectation was not universal: in some clinical settings babies were not monitored or at least, not in 
front of parents. In other cases, NAS was expected, assumed and assiduously searched for in the 
form of biomedical evidence. Despite the uncertainty around diagnosis or identification of NAS, in 
some accounts it appeared that confirmation of NAS was needed: scores might guide treatment 
pathways – to NNU or not; a confirmed diagnosis of NAS might be seen as simultaneously confirming 
maternal drug misuse among clinical and lay people alike. Similarly, where NAS was potentially 
identified, different treatments were possible, with different implications for parents – the NNU in 
particular, emerged as a site of contestation, and concern.  The wider social structures that can so 
sharply define maternal drug use as harmful and toxic to babies thus play out differently in different 
contexts. It is this crucial nuancing that Mol’s ethnographic approach adds, and which we suggest 
presents a useful additional perspective to complement the notion of social diagnosis; reminding us 
to consider carefully the contexts (including power relations) in which diagnosis plays out.  
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Following Fraser et al. (2014), we suggest that uncertainty around NAS may mean there is scope to 
introduce alternative narratives, and alternative practices of care for babies at risk of ‘NAS’, that may 
be experienced as more supportive by parents. This might take the form of resisting scoring of NAS 
as inherently uncertain and as such a problematic clinical category.  Care and treatment could 
respond instead to the needs of individual babies and their parents, without the explicit naming the 
‘problem’ of NAS. Alternatively, the ‘diagnosis’ of NAS could be framed more explicitly as a ‘social 
diagnosis’ – one which is understood by parents and professionals alike as relating to the complex 
interplay between biological and sociological factors – including entrenched inequalities and 
marginalisation facing many parents who use drugs. This approach might serve to shift attention 
away from the role of ‘maternal drug use’ in producing NAS, towards a broader range of social 
challenges faced by parents. Perhaps in drawing on the concept of social diagnosis we might connect 
negative, stigmatising framings of drug use in pregnancy to the intersection of socioeconomic, 
gender and (in some contexts) racial inequalities, with those most affected by punitive responses to 
drug use in pregnancy often being those with the least power. Approaching NAS as a social 
diagnosis, while recognising its multiple framings, may enable responses to clinical uncertainty which 
avoid, rather than promote, further marginalisation of parents who use drugs.  
Such suggestions pose significant challenges, though, in terms of how NAS might be otherwise (Mol, 
1999). Indeed, we have shown how currently uncertainties around NAS provide space for some of 
the more punitive responses reported in our data and elsewhere (Boyd 1999, Knight 2015), rather 
than the more caring alternatives that were occasionally reported in our data. Our analysis also 
provokes significant political questions about who might choose from a range of different 
productions of NAS and how easily alternative (less stigmatising) approaches to responding to drug-
exposed infants might be incorporated into current practice, given prevailing (negative) cultural 
attitudes towards addiction and motherhood.   
One way in which such questions might be at least partly resolved is by promoting a more inclusive 
culture in the clinical setting in which diagnoses are made. For instance, the SENSES framework 
(Nolan et al., 2003) focuses on inclusive decision making between service providers and service users 
(including family).  Of importance is the creation of an operational culture in which staff and service 
users share a philosophy of care which values people rather than tasks (perhaps including diagnosis, 
or ‘proving’ the presence or absence of NAS). This may provide a framework which is able to 
empower service providers and families to challenge existing practice and decision making in a space 
where seeks to recognise all parties as experts, and where existing tensions between each may exist. 
This approach has been used with promising initial indications in family-focused approaches in adult 
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drug services (Orr et al., 2014), and as such may provide a useful approach in reimagining care for 
families affected by NAS.   
Acknowledgements 
This project was funded by Edinburgh and Lothian Health Foundation (ELHF), grant reference 10-
314. The paper benefitted greatly from feedback from anonymous reviewers and editors. Special 
thanks to all of the parents and professionals who took part; as well as those who supported 
recruitment for the study.  
References  
ACMD (2003). Hidden Harm: responding to the needs of children of problem drug users. London: 
Home Office. 
Atkinson, P. (1984). Training for certainty. Social Science & Medicine, 19, 949-956. 
Atwood, E.C., Sollender, G., Hsu, E., Arsnow, C., Flanagan, V., Celenza, J., et al. (2016). A Qualitative 
Study of Family Experience With Hospitalization for Neonatal Abstinence Syndrome. Hospital 
Pediatrics, 6, 626-632. 
Benoit, C., Stengel, C., Marcellus, L., Hallgrimsdottir, H., Anderson, J., MacKinnon, K., et al. (2014). 
Providers’ constructions of pregnant and early parenting women who use substances. 
Sociology of Health & Illness, 36, 252-263. 
Blaxter, M. (1978). Diagnosis as category and process: The case of alcoholism. Social Science & 
Medicine. Part A: Medical Psychology & Medical Sociology, 12, 9-17. 
Boyd, S.C. (1999). Mothers and Illicit Drugs: Transcending the Myths. Toronto: University of Toronto 
Press. 
Boyd, S.C. (2004). From witches to crack moms: women, drug law, and policy. Durham: Carolina 
Academic Press. 
Brown, P. (1990). The name game: Toward a sociology of diagnosis. Journal of Mind and Behavior, 
11, 385-406. 
Brown, P., Lyson, M., & Jenkins, T. (2011). From diagnosis to social diagnosis. Social Science & 
Medicine, 73, 939-943. 
Chandler, A., Whittaker, A., Cunningham-Burley, S., Williams, N., McGorm, K., & Mathews, G. (2013). 
Substance, structure and stigma: Parents in the UK accounting for opioid substitution 
therapy during the antenatal and postnatal periods. International Journal of Drug Policy, 24, 
e35-e42. 
Cleary, B.J., Donnelly, J., Strawbridge, J., Gallagher, P.J., Fahey, T., Clarke, M., et al. (2010). 
Methadone dose and neonatal abstinence syndrome—systematic review and meta-analysis. 
Addiction, 105, 2071-2084. 
Cleveland, L.M., & Bonugli, R. (2014). Experiences of Mothers of Infants with Neonatal Abstinence 
Syndrome in the Neonatal Intensive Care Unit. Journal of Obstetric, Gynecologic & Neonatal 
Nursing, 43, 318-329. 
Flavin, J., & Paltrow, L.M. (2010). Punishing Pregnant Drug-Using Women: Defying Law, Medicine, 
and Common Sense. Journal of Addictive Diseases, 29, 231-244. 
Fox, R.C. (2000). Medical Uncertainty Revisited. In G.L. Albrecht, R. Fitzpatrick, & S.C. Scrimshaw 
(Eds.), Handbook of Social Studies in Health and Medicine. London: SAGE Publications Ltd. 
Fraser, S., Moore, D., & Keane, H. (2014). Habits: Remaking Addiction. Basingstoke Palgrave 
Macmillan. 
Fraser, S., & valentine, k. (2008). Substance and Substitution. Basingstoke: Palgrave Macmillan. 
Gregory, J. (2010). (M)Others in Altered States: Prenatal Drug-Use, Risk, Choice, and Responsible 
Self-Governance. Social & Legal Studies, 19, 49-66. 
Special Issue: Uncertainty 
18 
 
Hennink, M., Hutter, I., & Bailey, A. (2011). Qualitative Research Methods. London: Sage. 
Hudak, M.L., Tan, R.C., Frattarelli, D.A.C., Galinkin, J.L., Green, T.P., Neville, K.A., et al. (2012). 
Neonatal Drug Withdrawal. Pediatrics, 129, e540-e560. 
Jansson, L.M., & Velez, M. (2012). Neonatal abstinence syndrome. Current Opinion in Pediatrics, 24, 
252-258 210.1097/MOP.1090b1013e32834fdc32833a. 
Jenkins, T.M., & Short, S.E. (2017). Negotiating intersex: A case for revising the theory of social 
diagnosis. Social Science & Medicine, 175, 91-98. 
Jutel, A. (2009). Sociology of diagnosis: a preliminary review. Sociology of Health & Illness, 31, 278-
299. 
Jutel, A., & Nettleton, S. (2011). Towards a sociology of diagnosis: Reflections and opportunities. 
Social Science & Medicine, 73, 793-800. 
Kenny, K.S., Barrington, C., & Green, S.L. (2015). “I felt for a long time like everything beautiful in me 
had been taken out”: Women's suffering, remembering, and survival following the loss of 
child custody. International Journal of Drug Policy, 26, 1158–1166. 
Kilty, J.M., & Dej, E. (2012). Anchoring Amongst the Waves: Discursive Constructions of Motherhood 
and Addiction. Qualitative Sociology Review, 9, 6-23. 
Klee, H., Jackson, M., & Lewis, S. (2002). Drug misuse and motherhood. London: Routledge. 
Knight, K.R. (2015). addicted. pregnant. poor. Durham: Duke University Press. 
Knopf, A. (2016). Baby's mother is the best treatment for neonatal abstinence syndrome. Alcoholism 
& Drug Abuse Weekly, 28, 1-4. 
Marcellus, L. (2007). Neonatal abstinence syndrome: reconstructing the evidence. Neonatal 
Network: NN, 26, 33-40. 
McQueen, K., Murphy-Oikonen, J., & Desaulniers, L. (2015). Maternal Substance Use and Neonatal 
Abstinence Syndrome: A Descriptive Study. Maternal and Child Health Journal, 19, 1756-
1765. 
Mol, A. (1999). Ontological politics. A word and some questions. The Sociological Review, 47, 74-89. 
Mol, A. (2002). The Body Multiple: Ontology in Medical Practice. Durham: Duke University Press. 
Morris, M., Seibold, C., & Webber, R. (2012). Drugs and having babies: An exploration of how a 
specialist clinic meets the needs of chemically dependent pregnant women. Midwifery, 28, 
163-172. 
Nolan, M., Grant, G., Keady, J., & Lundh, U. (2003). New directions for partnerships:Relationship-
centred care. In M. Nolan, U. Lundh, G. Grant, & J. Keady (Eds.), Partnerships in family care: 
Understanding the care giving career. Maidenhead: Open University Press. 
Orr, L.C., Elliott, L., & Barbour, R.S. (2014). Promoting family-focused approaches within adult drug 
services: The potential of the ‘Senses Framework’. International Journal of Drug Policy, 25, 
888-896. 
Powis, B., Gossop, M., Bury, C., Payne, K., & Griffiths, P. (2000). Drug-using mothers: social, 
psychological and substance use problems of women opiate users with children. Drug and 
Alcohol Review, 19, 171-180. 
Pryor, J.R., Maalouf, F.I., Krans, E.E., Schumacher, R.E., Cooper, W.O., & Patrick, S.W. (2017). The 
opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum 
of care. Archives of Disease in Childhood - Fetal and Neonatal Edition, 102, F183. 
QSR International Pty Ltd. (2012). NVivo qualitative data analysis software; Version 10. 
Radcliffe, P. (2009). Drug use and motherhood: strategies for managing identity. Drugs and Alcohol 
Today, 9, 17-21. 
Radcliffe, P., Flávia Pires Lucas d'Oliveira, A., Lea, S., dos Santos Figueiredo, W., & Gilchrist, G. (2016). 
Accounting for intimate partner violence perpetration. A cross-cultural comparison of 
English and Brazilian male substance users' explanations. Drug and Alcohol Review, n/a-n/a. 
Rafalovich, A. (2005). Exploring clinician uncertainty in the diagnosis and treatment of attention 
deficit hyperactivity disorder. Sociology of Health & Illness, 27, 305-323. 
Special Issue: Uncertainty 
19 
 
Rhodes, T., Bernays, S., & Houmoller, K. (2010). Parents who use drugs: Accounting for damage and 
its limitation. Social Science & Medicine, 71, 1489-1497. 
Riessman, C.K. (2008). Narrative Methods for the Human Sciences. Thousand Oaks: Sage. 
Shriver, T.E., & Bodenhamer, A. (2018). The enduring legacy of black lung: environmental health and 
contested illness in Appalachia. Sociology of Health & Illness, 40, 1361-1375. 
Sword, W., Jack, S., Niccols, A., Milligan, K., Henderson, J., & Thabane, L. (2009). Integrated programs 
for women with substance use issues and their children: a qualitative meta-synthesis of 
processes and outcomes. Harm Reduction Journal, 6. 
Vrecko, S. (2010). Birth of a brain disease: science, the state and addiction neuropolitics. History of 
the Human Sciences, 23, 52-67. 
Whittaker, A., Chandler, A., Cunningham-Burley, S., Midgley, P., Elliott, L., & Cooper, S. (2019). 
Problematisation and regulation: Bodies, risk, and recovery within the context of Neonatal 
Abstinence Syndrome. International Journal of Drug Policy, 68, 139-146.  
Wolff, K., & Perez-Montejano, R. (2014). Opioid neonatal abstinence syndrome: controversies and 
implications for practice. Curr Drug Abuse Rev, 7, 44-58. 
 
 
i In each of these cases the charts indicate higher scores for more severe symptoms.  
                                                          
